IMAJ | volume 27
Journal 5, May 2025
pages: 290-296
1 Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
2 Department of Gastroenterology, Meir Medical Center, Kfar Saba, Israel
3 Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel
4 Liver Unit, Galilee Medical Center, Nahariya, Israel
Summary
Background:
High prevalence of hepatitis C (HCV) among people with severe mental illness (SMI) is attributed mostly to current or past intravenous (IV) drug use. However, such history may disappear from patient files over time, especially in chronic SMI with prolonged psychiatric admissions.
Objectives:
To explore HCV and SMI cross-morbidity (HCV/SMI) in a hospitalized population.
Methods:
In this observational, retrospective, historical computerized study we examined prevalence, characteristics, and outcomes of patients with HCV/SMI compared to HCV alone in patients admitted to an Israeli hospital 1 January 2005 to 31 December 2020.
Results:
Of 1638 eligible HCV patients, 219 (13.4%) were HCV/SMI. Significantly more native Israelis showed HCV/SMI than HCV alone (36.1% vs. 18.1%,
P = 0.013) and history of IV drug use (60.3% vs. 32.4%,
P < 0.001). Among Israeli natives, more Jews were SMI/HCV compared to HCV only (67.1% vs. 45%,
P < 0.01). Among non-native Israelis, immigration age was lower in SMI/HCV compared to HCV only (27.97 vs. 37.23 years,
P < 0.001). No differences were found in mortality or cirrhosis, although HCV/SMI patients experienced earlier mortality compared to HCV alone (61.42 ± 14.3 vs. 72.8 ± 14.6 years,
P < 0.001). Cirrhosis among HCV/SMI patients was a risk factor for early mortality (hazard ratio 5.528, 95% confidence interval 3.721–8.213).
Conclusions:
HCV/SMI is related to early mortality, particularly with cirrhosis. There is significantly high SMI prevalence in hospitalized HCV patients, representing a unique at-risk population. Identification during hospitalization and medical recommendations at discharge may fill the gaps.